HPV vaccine prices need to come down, Nobel winner says
This article was originally published in Scrip
Current vaccines for cervical cancer are priced too high in many markets, while expanded vaccination programmes against the human papillomavirus (HPV) would bring a number of benefits, the joint winner of last year's Nobel Prize in Physiology or Medicine has told Scrip.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.